Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Dabrafenib | The serum concentration of Dexrabeprazole can be decreased when it is combined with Dabrafenib. |
| Amphetamine | Dexrabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Atazanavir | Dexrabeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Dexrabeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Dexrabeprazole. |
| Dabigatran etexilate | Dexrabeprazole can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Dexrabeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Dexrabeprazole can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dextroamphetamine | Dexrabeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Erlotinib | Dexrabeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluconazole | The metabolism of Dexrabeprazole can be decreased when combined with Fluconazole. |
| Gefitinib | Dexrabeprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Dexrabeprazole can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Dexrabeprazole can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Dexrabeprazole can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrexate | The excretion of Methotrexate can be decreased when combined with Dexrabeprazole. |
| Methylphenidate | Dexrabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dexmethylphenidate | Dexrabeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Nelfinavir | The serum concentration of Nelfinavir can be decreased when it is combined with Dexrabeprazole. |
| Nilotinib | The serum concentration of Nilotinib can be decreased when it is combined with Dexrabeprazole. |
| Pazopanib | Dexrabeprazole can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Posaconazole | Dexrabeprazole can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Dexrabeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Rilpivirine | Dexrabeprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Dexrabeprazole can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Dexrabeprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Saquinavir | The serum concentration of Saquinavir can be increased when it is combined with Dexrabeprazole. |
| Voriconazole | The metabolism of Dexrabeprazole can be decreased when combined with Voriconazole. |
| Luliconazole | The serum concentration of Dexrabeprazole can be increased when it is combined with Luliconazole. |
| Levothyroxine | Dexrabeprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Dexrabeprazole. |
| Captopril | Dexrabeprazole can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Dexrabeprazole. |
| Rifampin | Dexrabeprazole can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Memantine | Dexrabeprazole may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Dexrabeprazole. |
| Mesalazine | Dexrabeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolate mofetil | Dexrabeprazole can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | Dexrabeprazole can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Dexrabeprazole. |
| Alendronic acid | The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexrabeprazole. |
| Ibandronate | The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexrabeprazole. |
| Clodronic acid | The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexrabeprazole. |
| Etidronic acid | The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Dexrabeprazole. |
| Tiludronic acid | The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Dexrabeprazole. |
| Incadronic acid | The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Dexrabeprazole. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Dexrabeprazole. |
| Ketoconazole | Dexrabeprazole can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lumacaftor | The serum concentration of Dexrabeprazole can be decreased when it is combined with Lumacaftor. |
| Tacrolimus | The metabolism of Tacrolimus can be decreased when combined with Dexrabeprazole. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Dexrabeprazole. |
| Fluvoxamine | The metabolism of Dexrabeprazole can be decreased when combined with Fluvoxamine. |
| Ticlopidine | The metabolism of Dexrabeprazole can be decreased when combined with Ticlopidine. |
| Chloramphenicol | The metabolism of Dexrabeprazole can be decreased when combined with Chloramphenicol. |
| Lansoprazole | The metabolism of Dexrabeprazole can be decreased when combined with Lansoprazole. |
| Imipramine | The metabolism of Dexrabeprazole can be decreased when combined with Imipramine. |
| Fluoxetine | The metabolism of Dexrabeprazole can be decreased when combined with Fluoxetine. |
| Zafirlukast | The metabolism of Dexrabeprazole can be decreased when combined with Zafirlukast. |
| Isoniazid | The metabolism of Dexrabeprazole can be decreased when combined with Isoniazid. |
| Miconazole | The metabolism of Dexrabeprazole can be decreased when combined with Miconazole. |
| Gemfibrozil | The metabolism of Dexrabeprazole can be decreased when combined with Gemfibrozil. |
| Clomipramine | The metabolism of Dexrabeprazole can be decreased when combined with Clomipramine. |
| Stiripentol | The metabolism of Dexrabeprazole can be decreased when combined with Stiripentol. |
| Efavirenz | The metabolism of Dexrabeprazole can be decreased when combined with Efavirenz. |
| Eslicarbazepine acetate | The metabolism of Dexrabeprazole can be decreased when combined with Eslicarbazepine acetate. |
| Prussian blue | Dexrabeprazole can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron sucrose | Dexrabeprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric ammonium citrate | Dexrabeprazole can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxsil | Dexrabeprazole can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxides | Dexrabeprazole can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric sulfate | Dexrabeprazole can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous bisglycinate | Dexrabeprazole can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gleptoferron | Dexrabeprazole can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perflubutane | Dexrabeprazole can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium feredetate | Dexrabeprazole can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric hydroxide | Dexrabeprazole can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric cation | Dexrabeprazole can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous gluconate | Dexrabeprazole can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous succinate | Dexrabeprazole can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous fumarate | Dexrabeprazole can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetraferric tricitrate decahydrate | Dexrabeprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxyhydroxide | Dexrabeprazole can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron Dextran | Dexrabeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron | Dexrabeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric pyrophosphate | Dexrabeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric maltol | Dexrabeprazole can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron polymaltose | Dexrabeprazole can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Apalutamide | The serum concentration of Dexrabeprazole can be increased when it is combined with Apalutamide. |
| Bortezomib | The metabolism of Dexrabeprazole can be decreased when combined with Bortezomib. |
| Sildenafil | The metabolism of Dexrabeprazole can be decreased when combined with Sildenafil. |
| Pantoprazole | The metabolism of Dexrabeprazole can be decreased when combined with Pantoprazole. |
| Citalopram | The metabolism of Dexrabeprazole can be decreased when combined with Citalopram. |
| Olanzapine | The metabolism of Dexrabeprazole can be decreased when combined with Olanzapine. |
| Omeprazole | The metabolism of Dexrabeprazole can be decreased when combined with Omeprazole. |
| Clozapine | The metabolism of Dexrabeprazole can be decreased when combined with Clozapine. |
| Nilutamide | The metabolism of Dexrabeprazole can be decreased when combined with Nilutamide. |
| Esomeprazole | The metabolism of Dexrabeprazole can be decreased when combined with Esomeprazole. |
| Ethanol | The metabolism of Dexrabeprazole can be decreased when combined with Ethanol. |
| Zonisamide | The metabolism of Dexrabeprazole can be decreased when combined with Zonisamide. |
| Tipranavir | The metabolism of Dexrabeprazole can be decreased when combined with Tipranavir. |